DK0821689T3 - Tumorproteaseaktiverede prolægemidler af phosphoramidsennepanaloger - Google Patents
Tumorproteaseaktiverede prolægemidler af phosphoramidsennepanalogerInfo
- Publication number
- DK0821689T3 DK0821689T3 DK96912645T DK96912645T DK0821689T3 DK 0821689 T3 DK0821689 T3 DK 0821689T3 DK 96912645 T DK96912645 T DK 96912645T DK 96912645 T DK96912645 T DK 96912645T DK 0821689 T3 DK0821689 T3 DK 0821689T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino group
- groups
- phosphoramide mustard
- activated prodrugs
- guanidino
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- RJXQSIKBGKVNRT-UHFFFAOYSA-N phosphoramide mustard Chemical class ClCCN(P(O)(=O)N)CCCl RJXQSIKBGKVNRT-UHFFFAOYSA-N 0.000 title abstract 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- -1 p-guanidino-benzoyloxy groups Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 108090000371 Esterases Proteins 0.000 abstract 1
- BKCJZNIZRWYHBN-UHFFFAOYSA-N Isophosphamide mustard Chemical compound ClCCNP(=O)(O)NCCCl BKCJZNIZRWYHBN-UHFFFAOYSA-N 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/425,477 US5659061A (en) | 1995-04-20 | 1995-04-20 | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
| PCT/US1996/004882 WO1996033198A1 (en) | 1995-04-20 | 1996-04-11 | Tumor protease activated prodrugs of phosphoramide mustard analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0821689T3 true DK0821689T3 (da) | 2001-10-22 |
Family
ID=23686730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96912645T DK0821689T3 (da) | 1995-04-20 | 1996-04-11 | Tumorproteaseaktiverede prolægemidler af phosphoramidsennepanaloger |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5659061A (da) |
| EP (1) | EP0821689B1 (da) |
| JP (1) | JPH11504009A (da) |
| AT (1) | ATE202781T1 (da) |
| AU (1) | AU697110B2 (da) |
| CA (1) | CA2215264A1 (da) |
| DE (1) | DE69613691T2 (da) |
| DK (1) | DK0821689T3 (da) |
| ES (1) | ES2160815T3 (da) |
| GR (1) | GR3036796T3 (da) |
| PT (1) | PT821689E (da) |
| WO (1) | WO1996033198A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ291368A (en) * | 1994-08-19 | 1999-04-29 | Wallone Region | A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices |
| US5952294A (en) * | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| EP0933030B1 (en) * | 1997-12-22 | 2006-07-26 | Givaudan SA | Pungent flavor components |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| WO2000071134A1 (en) * | 1999-05-24 | 2000-11-30 | Southern Research Institute | Isophosphoramide mustard analogs and use thereof |
| WO2001004130A1 (en) | 1999-07-14 | 2001-01-18 | Purdue Research Foundation | Phosphoramide compounds |
| CA2391534A1 (en) * | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| WO2001095943A2 (en) | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Prodrug compounds with an oligopeptide having an isoleucine residue |
| AU2001286727A1 (en) * | 2000-08-24 | 2002-03-04 | Coulter Pharmaceutical, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| RU2414475C2 (ru) * | 2005-06-29 | 2011-03-20 | Трешолд Фармасьютикалз, Инк. | Пролекарства фосфорамидатных алкилаторов |
| EP2792670A1 (en) | 2006-10-03 | 2014-10-22 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates |
| US8518891B2 (en) * | 2006-11-29 | 2013-08-27 | Longqin Hu | Chemotherapeutic conjugates and methods of use |
| EP2114157B1 (en) | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| ES2547302T3 (es) * | 2007-04-06 | 2015-10-05 | Ziopharm Oncology, Inc. | Sales de mostaza de isofosforamida y análogos de las mismas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011484A1 (en) * | 1988-05-25 | 1989-11-30 | Research Corporation Technologies, Inc. | Phosphoramides useful as antitumor agents |
| US5274162A (en) * | 1991-12-13 | 1993-12-28 | Arnold Glazier | Antineoplastic drugs with bipolar toxification/detoxification functionalities |
| DE4309344A1 (de) * | 1993-03-23 | 1994-09-29 | Gerhard Prof Dr Eisenbrand | Antineoplastische Mittel mit verstärkter Wirksamkeit |
-
1995
- 1995-04-20 US US08/425,477 patent/US5659061A/en not_active Expired - Fee Related
-
1996
- 1996-04-11 EP EP96912645A patent/EP0821689B1/en not_active Expired - Lifetime
- 1996-04-11 AU AU55389/96A patent/AU697110B2/en not_active Ceased
- 1996-04-11 AT AT96912645T patent/ATE202781T1/de not_active IP Right Cessation
- 1996-04-11 PT PT96912645T patent/PT821689E/pt unknown
- 1996-04-11 CA CA002215264A patent/CA2215264A1/en not_active Abandoned
- 1996-04-11 DK DK96912645T patent/DK0821689T3/da active
- 1996-04-11 WO PCT/US1996/004882 patent/WO1996033198A1/en active IP Right Grant
- 1996-04-11 JP JP8531791A patent/JPH11504009A/ja not_active Ceased
- 1996-04-11 DE DE69613691T patent/DE69613691T2/de not_active Expired - Fee Related
- 1996-04-11 ES ES96912645T patent/ES2160815T3/es not_active Expired - Lifetime
-
2001
- 2001-10-04 GR GR20010401658T patent/GR3036796T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69613691T2 (de) | 2002-05-08 |
| EP0821689A1 (en) | 1998-02-04 |
| WO1996033198A1 (en) | 1996-10-24 |
| ES2160815T3 (es) | 2001-11-16 |
| ATE202781T1 (de) | 2001-07-15 |
| CA2215264A1 (en) | 1996-10-24 |
| AU697110B2 (en) | 1998-09-24 |
| PT821689E (pt) | 2001-12-28 |
| JPH11504009A (ja) | 1999-04-06 |
| GR3036796T3 (en) | 2002-01-31 |
| DE69613691D1 (de) | 2001-08-09 |
| AU5538996A (en) | 1996-11-07 |
| US5659061A (en) | 1997-08-19 |
| EP0821689B1 (en) | 2001-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0821689T3 (da) | Tumorproteaseaktiverede prolægemidler af phosphoramidsennepanaloger | |
| ITMI921601A1 (it) | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. | |
| BR9408151A (pt) | Processos de hidrocianação de precursor de catalisador | |
| MX9700222A (es) | Derivados de camptotecina. | |
| NZ334595A (en) | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage | |
| UA27224C2 (uk) | Арилалкіламіни, спосіб їх одержання та фармацевтична композиція | |
| GT200300240A (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos | |
| GT199900056A (es) | Nuevas dihidropirimidinas | |
| BR9713404A (pt) | ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos. | |
| HUP0000577A2 (hu) | Heptapeptid oxitocin analogók, e vegyületeket tartalmazó gyógyászati készítmények,továbbá eljárás előállításukra,valamint e vegyületek alkalmazása | |
| CO4790174A1 (es) | Analogos del peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen | |
| BR9806266A (pt) | "método de preparação de ácidos de amino carboxìlicos" | |
| HUP9902256A1 (hu) | Proteázgátló amidinoszármazékok, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| AR009572A1 (es) | Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso | |
| DK1040119T3 (da) | Hemiasterlinanaloger | |
| BR0315864A (pt) | Composições e processos para a modificação efeitos tóxicos de compostos proteináceos | |
| DE69722618D1 (en) | Peptide | |
| AR044175A1 (es) | Compuestos de cefemo | |
| BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo | |
| DK1180094T3 (da) | Kondenserede polycykliske aminosyrer som farmaceutiske midler | |
| PA8475701A1 (es) | Derivados de 3(2-oxo-[1,3']bipirrolidinil-3-ilidenmetil)-cephems | |
| ES2170922T3 (es) | Composicion farmaceutica a base de matrices lipofilas estabilizadas para la liberacion controlada de principios activos. | |
| CY1106058T1 (el) | Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις | |
| ES2111297T3 (es) | Nuevos esteres de acidos carboxilicos de 2-amino-7-(1,3-dihidroxi-2-propoximetil)purina, su preparacion asi como su empleo. | |
| PT1015415E (pt) | Novos processos estereosselectivos para a preparacao de analogos de gabapentina |